Cipla, Hetero receive drug controller's emergency approval for Remdesivir for severe Covid-19 patients

Remdesivir is an experimental drug from drug maker Gilead that has
shown to bring down the viral load on patients and hence help in
faster discharge. The efficacy of the drug on severe patients is still
under study. US drug maker Gilead has given voluntary licenses to five
Indian companies to manufacture this drug.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/cipla-hetero-receive-drug-controllers-emergency-approval-for-remdesivir-for-severe-covid-19-patients/articleshow/76485542.cms

Comments

Popular posts from this blog

TIGS-CI Biological Sciences Research Assistant Recruitment, Apply Online

Biotecnika Times Newsletter 30.11.2021 CSIR-IGIB Rs 1.5 Lakh pm Pay Job, ACTREC High Pay

Biotecnika Times Newsletter 25.10.2021 Tata Innovation Fellowship 2021, NCCS PhD Admission